(NY: NRXS )

2.590 UNCHANGED

Streaming Delayed Price Updated: 8:00 PM EDT, Nov 1, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about NRXS

NRXS Stock Earnings: Neuraxis Reported Results for Q2 2024

August 09, 2024

Neuraxis just reported results for the second quarter of 2024.

Via InvestorPlace

NRXS Stock Earnings: Neuraxis Reported Results for Q1 2024

May 22, 2024

Neuraxis just reported results for the first quarter of 2024.

Via InvestorPlace

NRXS Stock Earnings: Neuraxis Misses Revenue for Q4 2023

April 16, 2024

NRXS stock results show that Neuraxis missed on revenue for the fourth quarter of 2023.

Via InvestorPlace

Earnings Scheduled For April 9, 2024

April 09, 2024

Companies Reporting Before The Bell • Tilray Brands (NASDAQ:TLRY) is projected to report quarterly loss at $0.05 per share on revenue of $198.62 million.

Via Benzinga

With Only 1.21 Million In The Trading Float, NeurAxis Stock Volatility Exposes An Opportunity, Not A Deterrent ($NRXS)

September 19, 2023

Via AB Newswire

Exposures Product Safety

SoftBank-Owned Arm, Instacart File To Go Public

August 27, 2023

Via Talk Markets

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

September 12, 2023

Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.

Via Benzinga

EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome

September 12, 2023

NeurAxis Inc (NYSE: NRXS) announced the publication of a Prospective study evaluating the efficacy of IB-Stim in children featured in the September 2023 Frontiers in Pain Research.

Via Benzinga

CEO Spotlight: NeurAxis CEO Explains His Better Way Of Treating Pediatric IBS And FAP ($NRXS)

September 06, 2023

Via AB Newswire

NeurAxis Looks To Revolutionize The Treatment Of Adolescent Stomach Issues

August 30, 2023

NeurAxis, Inc. (NYSEAMERICAN: NRXS) looks to revolutionize how pediatric irritable bowel syndrome (IBS) and functional abdominal pain (FAP) are treated.

Via Benzinga

EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids

August 29, 2023

NeurAxis Inc (NYSE: NRXS) highlighted A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS), a...

Via Benzinga

NeurAxis Announces Positive University of Michigan IB-Stim™ Cost Effectiveness Study at ANMS 2023

August 15, 2023

From NeurAxis, Inc.

Via GlobeNewswire

Alcoholic Beverage Marketing Company LQR Debuts On Nasdaq

August 13, 2023

LQR House, which provides digital marketing and branding services to the alcohol industry, went public on Thursday, raising $5 million million in its IPO. Meanwhile NeurAxis, raised $7 million in its...

Via Talk Markets

Topics Initial Public Offering

Exposures Securities Market

Goldman Small Cap Research Publishes New Research Report on NeurAxis, Inc.

August 11, 2023

Via ACCESSWIRE

NeurAxis Highlights Current Commercial Insurance Coverage with BCBS Massachusetts, BCBS South Carolina, BCBS Nebraska, and Quartz Wisconsin

August 10, 2023

From NeurAxis, Inc.

Via GlobeNewswire

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.